We are delighted to announce BioTrinity 2011 is already bigger than in BioTrinity 2010, with registrations running 22% up on the same point last year, and partnering a whopping 71% up setting new records. It is on track to reach 750 delegates by April 12-14. Interest is being driven by the broad access the conference provides to key people within both global corporates and investment firms.  However, registration closes in just over two weeks so register now.

BioTrinity brings together great minds, smart money as well as Global Corporates.

Don’t miss the opportunity to meet with senior licensing and venture professionals from these global firms: Abbott, Allergan, AstraZeneca, Baxter, Boehringer, Lilly, GSK, J&J Dev Corp, Lundbeckfund, Merck Serono Ventures, Merck Sharp & Dohme, MP Healthcare Venture Management, Novartis, Pfizer, Roche, Sanofi, Shanghai Fosun Pharma, Shire, Smith and Nephew, SR One, Takeda Pharmaceuticals Europe, Takeda Ventures, and Teva among the 750 delegates attending BioTrinity on April 12-14 at the Newbury Racecourse, UK. 

Statistics show BioTrinity is on track to grow at least 20% again this year, with 76 investment firms investing in biotech and medtech already confirmed.  See who else is attending.

The seniority of these delegates shows that BioTrinity is the place to make those partnering connections that will get the deal done.  Register now and start partnering with:

• Director, Venture Investments, Abbott Biotech Ventures
• Partner, Abingworth
• VP Business Development, EAME, Allergan
• VP Strategic Partnering and Business Development, AstraZeneca
• Pharma Partner Executive, Baxter
• Investment Manager, Boehringer Ingelheim GmbH (Germany)
• Partner, DFJ Espirt
• Executive Director, Global External R&D, Europe and MENA, Eli Lilly
• Partner, Edmond de Rothschild Investment Partners
• Director Scientific Opportunities, GSK (CEEDD)
• Chairman, Inventages Venture Capital
• Executive Director Business Development, Ironwood Pharmaceuticals
• Vice President, Venture Investments, J&J Dev Corp (US)
• Senior Investment Manager, Lundbeckfund (Denmark)
• Head of Merck Serono Ventures (Switzerland)
• Senior Director and Head, Licensing and External Research Europe, MSD (Merck Sharp & Dohme Limited)
• Senior Manager, MP Healthcare Venture Management (US)
• Director, Global Alliance Management, Oncology Business Development and Licensing, Novartis Oncology
• Senior Partner, Novo A/S (Denmark)
• Head, Cardiovascular, Metabolic and Entero/Endocrine Diseases, External Research and Development Innovation, Pfizer, Inc.
• Strategic Business Partner, Communication, Roche Pharma Partnering
• sanofi-aventis recherche & développement, Partnering & Innovation, Sanofi Aventis
• Partner, Seventures Partners
• Investment Director, Shanghai Fosun Pharma (China)
• SVP, Strategic Investment Group, Shire
• Director, Business Development, Shire
• Science Manager, Smith and Nephew
• Vice President, Partner, SR One
• Senior Director, Global Business Development, Takeda Pharmaceuticals Europe
• President & CEO, Takeda Ventures, Inc (US)
• Senior Partnering Director, Teva Innovative Ventures, Teva

The testimonials say it all:  

"The partnering system was excellent. Coupled to the ability to meet senior BD&L and M&A people from Big Pharma, this event was an unprecedented success for Prosonix.", David Hipkiss, CEO, Prosonix

BioTrinity is a "Very good opportunity to meet and have introductory discussions with a number of companies who would otherwise be very difficult for a small biotech to have access to.", Vic Laville, CFO, IQur

"BioTrinity 2010 was by far the most effective and best organised event of its type that I have attended. We now have the opportunity to develop several strategic partnership relationships that it would otherwise have taken us months to initiate.", Paul Davie, Inhibox

Register now to book your private meetings from a selection of 750 delegates from 20 countries and over 450 companies; including 76 world renowned investment firms, senior licensing executives from big pharma, and senior management from innovative R&D medtech and biotech companies. Save even more on BioTrinity® by joining OBN: to get £150 off on every one of your company’s BioTrinity registrations.  

I’d like to take this opportunity to thank the whole life sciences community for adopting BioTrinity as your partnering conference, and I hope together we will all again achieve much both during conference and in the months following,

Best wishes – hope to see you in Newbury,